Cargando…
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
Venous thromboembolism (VTE) is a common and serious complication in patients with cancer; treatment guidelines recommend extended therapy of ≥6 months with low-molecular-weight heparin (LMWH) for treatment and prevention of recurrent VTE (rVTE) in this population. This post hoc analysis used data f...
Autores principales: | Woodruff, Seth, Feugère, Guillaume, Abreu, Paula, Heissler, Joseph, Ruiz, Marcia T., Jen, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040733/ https://www.ncbi.nlm.nih.gov/pubmed/27344439 http://dx.doi.org/10.1007/s11239-016-1386-8 |
Ejemplares similares
-
Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
por: Dranitsaris, George, et al.
Publicado: (2017) -
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study
por: Woodruff, Seth, et al.
Publicado: (2019) -
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
por: Geldhof, Vincent, et al.
Publicado: (2014) -
Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020) -
Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)